Drug Price Trends for repaglinide

Average Pharmacy Cost for repaglinide

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
REPAGLINIDE 2 MG TABLET	65862-0672-01	0.11632	EACH	2025-03-19
REPAGLINIDE 0.5 MG TABLET	33342-0248-11	0.07934	EACH	2025-03-19
REPAGLINIDE 0.5 MG TABLET	57237-0157-01	0.07934	EACH	2025-03-19
REPAGLINIDE 1 MG TABLET	33342-0249-11	0.12066	EACH	2025-03-19

Market Analysis and Price Projections for Repaglinide

Introduction to Repaglinide

Repaglinide, a member of the meglitinides drug class, is widely used for the treatment of type 2 diabetes. It is known for its rapid onset and short duration of action, making it an effective option for controlling postprandial hyperglycemia.

Global Market Size and Growth Projections

The global Repaglinide market has been experiencing significant growth, driven by several key factors. As of 2023, the market size was valued at USD 85 billion and is projected to reach USD 109 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 3.6% from 2024 to 2031[1].

Drivers of Market Growth

Several factors are driving the growth of the Repaglinide market:

Increasing Prevalence of Type 2 Diabetes

The global rise in the incidence of type 2 diabetes is a major driver, as it increases the demand for effective glucose-lowering drugs like Repaglinide[1].

Pharmacological Advantages

Repaglinide's short half-life and rapid onset of action make it a preferred choice for managing postprandial hyperglycemia, contributing to its market expansion[1].

Healthcare Infrastructure Development

Improvements in healthcare infrastructure, particularly in developing countries, are making Repaglinide more accessible, thereby driving market growth[1].

Generic Versions

The launch of generic versions of Repaglinide is expected to enhance accessibility and affordability, further boosting market penetration[1].

Market Segmentation

The Repaglinide market is segmented based on several criteria:

By Product

• Above 99%: This segment includes high-purity Repaglinide products.
• Below 99%: This segment includes lower-purity versions, often used in different formulations[1].

By Application

• Tablet: The most common form of Repaglinide administration.
• Capsule: Another form in which Repaglinide is available.
• Other: Includes other formulations and delivery methods[1].

By Geographical Region

• North America: Includes the U.S., Canada, and Mexico.
• Europe: Includes Germany, the UK, France, and the rest of Europe.
• Asia-Pacific: Includes China, Japan, India, and other countries in the region.
• South America and Middle-East and Africa: Other significant regions contributing to the global market[1].

Competitive Landscape

The Repaglinide market is characterized by a competitive landscape involving several major players:

Key Market Players

• Novo Nordisk: Known for its brand Novonorm, which has a significant market share, especially in China[3].
• Haoson Pharmaceutical, Tianjin Kangrui Pharmaceutical, and Beijing Wansheng Pharmaceutical: Other notable players in the market[3].

Pricing and Cost Analysis

The cost of Repaglinide can vary based on the dosage, quantity, and pharmacy.

Price Guide for Repaglinide

• 0.5 mg Oral Tablet: Prices range from $66.88 for 100 tablets, with a per-unit cost of $0.67 to $3.21[2].
• 1 mg Oral Tablet: Prices start from $23.68 for 30 tablets, with a per-unit cost of $0.79[2].
• 2 mg Oral Tablet: Prices start from $37.46 for 100 tablets, with a per-unit cost of $0.37[2].

Generic Versions

Generic versions of Repaglinide are available, which can significantly reduce the cost. For example, a generic version of Prandin (Repaglinide) can cost as low as $17.89 for 30 tablets[5].

Market Trends and Outlook

Increasing Demand

The rising global incidence of type 2 diabetes and the need for effective glucose management are driving up demand for Repaglinide[1].

Technological Advancements

Improvements in drug formulation and delivery methods are expected to enhance the efficacy and convenience of Repaglinide, further boosting its market appeal[4].

Regulatory Environment

Regulatory approvals and the launch of new formulations are crucial for market growth. The report includes a detailed analysis of the regulatory landscape and its impact on the market[4].

Challenges and Restraints

Competition from Alternatives

The presence of other glucose-lowering drugs and therapies can pose a challenge to the growth of the Repaglinide market[1].

Economic Factors

Economic fluctuations and changes in healthcare policies can affect market dynamics and consumer spending on prescription drugs[4].

Porter’s Five Forces Analysis

The report includes a comprehensive Porter’s Five Forces analysis, which examines:

• Buyers’ Bargaining Power: The ability of consumers to influence prices.
• Suppliers’ Bargaining Power: The influence of suppliers on the market.
• Threat of New Entrants: The ease or difficulty with which new companies can enter the market.
• Threat of Substitutes: The availability of alternative products.
• Degree of Competition: The level of competition among existing market players[1].

Conclusion

The Repaglinide market is poised for significant growth driven by increasing demand for effective diabetes management, advancements in healthcare infrastructure, and the availability of generic versions. Understanding the market segmentation, competitive landscape, and pricing dynamics is crucial for stakeholders looking to navigate this market.

Key Takeaways

• The global Repaglinide market is expected to grow from USD 85 billion in 2023 to USD 109 billion by 2031.
• The market is driven by the increasing prevalence of type 2 diabetes and the pharmacological advantages of Repaglinide.
• Generic versions are expected to enhance market penetration and affordability.
• Major players include Novo Nordisk, Haoson Pharmaceutical, and others.
• The market is segmented by product, application, and geographical region.

FAQs

Q: What is the current market size of the Repaglinide market?

A: The Repaglinide market was valued at USD 85 billion in 2023[1].

Q: What is the projected growth rate of the Repaglinide market?

A: The market is expected to grow at a CAGR of 3.6% from 2024 to 2031[1].

Q: What are the main drivers of the Repaglinide market growth?

A: The main drivers include the increasing prevalence of type 2 diabetes, pharmacological advantages of Repaglinide, and improvements in healthcare infrastructure[1].

Q: Who are the major players in the Repaglinide market?

A: Major players include Novo Nordisk, Haoson Pharmaceutical, Tianjin Kangrui Pharmaceutical, and Beijing Wansheng Pharmaceutical[3].

Q: How does the cost of Repaglinide vary?

A: The cost varies based on dosage, quantity, and pharmacy, with generic versions offering significant cost savings[2][5].

Sources

1. Market Research Intellect: Repaglinide Market Size, Trends and Projections[1].
2. Drugs.com: Repaglinide Prices, Coupons, Copay Cards & Patient Assistance[2].
3. PR Newswire: World Repaglinide Market 2016-2021 Forecasts Analysis[3].
4. Cognitive Market Research: Repaglinide Market Report 2024 (Global Edition)[4].
5. Drugs.com: Prandin Prices, Coupons, Copay Cards & Patient Assistance[5].